Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects
This study is currently recruiting participants.
Verified September 2012 by MyoScience, Inc
Sponsor:
MyoScience, Inc
Information provided by (Responsible Party):
MyoScience, Inc
ClinicalTrials.gov Identifier:
NCT01681745
First received: September 5, 2012
Last updated: September 7, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is designed to characterize the biological response of the epidermis, dermis and subcutaneous tissue to treatment with the myoscience Cryo-Touch III system.
| Condition | Intervention | Phase |
|---|---|---|
|
Histological Response of Tissue to Cold |
Device: Treatment with Cryo-Touch III |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects |
Further study details as provided by MyoScience, Inc:
Primary Outcome Measures:
- Tissue Response [ Time Frame: 7 days ] [ Designated as safety issue: No ]The biological response of the treated tissue by the Cryo-Touch III device through gross pathology and histological assessment
Secondary Outcome Measures:
- Safety [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]All anticipated observations, adverse events and SAEs/UADEs will be assessed. Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADEs) will be recorded.
| Estimated Enrollment: | 30 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Treatment | Device: Treatment with Cryo-Touch III |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male or female, 18 to 70 years old
- Subject is willing and able to give written informed consent.
- Subject is committed to undergo an abdominoplasty procedure independent of this study.
- Subject is willing and able to comply with study instructions and commit to all visits for the duration of the study.
- Subject is in good general health and free of any disease state or physical condition that might impair evaluation or which in the investigator's opinion, expose the subject to an unacceptable risk by study participation.
Exclusion Criteria:
- Subject is currently enrolled in an investigational drug or a device study that specifically targets the abdominal area.
- Subject currently smokes.
- Subject has a clotting disorder and/or has used an anticoagulant (e.g., warfarin, clopidogrel, etc.) within seven (7) days prior to administration of the device.
- Subject has used oral or inhaled steroids in the last 14 days and/or has been a chronic user of inhaled or oral steroids in the past such that the investigator feels subject may have compromised wound healing.
- Subject has used topical steroids in the abdominal area within the last 30 days.
- Subject is on any systemic immunosuppressive therapy.
- Subject has had prior surgery and/or treatment that alters the subcutaneous anatomy of the target treatment sites: liposuction, cryolipolysis, or high-intensity focused ultrasound.
- History of abdominal hernia.
- Subject has any of the following conditions:
- Allergy or intolerance to lidocaine,
- Other local skin condition (e.g., skin infection) at target treatment site,
- Any physical or psychiatric condition that in the investigator's opinion would prevent adequate study participation.
- Chronic medical condition or use of medication that in the investigator's opinion would affect study participation or wound healing (such as diabetes, hepatitis, HIV, etc.).
- Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01681745
Contacts
| Contact: John Allison, PhD | 650-474-2600 | jallison@myoscience.com |
| Contact: Tracey Henry | 650-474-2600 | thenry@myoscience.com |
Locations
| United States, California | |
| 77 Plastic Surgery | Recruiting |
| San Francisco, California, United States, 94102 | |
| Principal Investigator: LARRY K FAN, MD | |
Sponsors and Collaborators
MyoScience, Inc
More Information
No publications provided
| Responsible Party: | MyoScience, Inc |
| ClinicalTrials.gov Identifier: | NCT01681745 History of Changes |
| Other Study ID Numbers: | MYO-0535 |
| Study First Received: | September 5, 2012 |
| Last Updated: | September 7, 2012 |
| Health Authority: | United States: Food and Drug Administration |
ClinicalTrials.gov processed this record on May 16, 2013